Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Niacin controlled release/laropiprant - Merck

Drug Profile

Niacin controlled release/laropiprant - Merck

Alternative Names: Cordaptive; ER niacin/laropiprant; ERN/LRPT - Merck; Extended-release niacin/immediate-release laropiprant; Laropiprant/ER niacin; Laropiprant/extended-release niacin; Laropiprant/nicotinic acid; MK-0524A; MK-524A; Nicotinic acid/laropiprant; Pelzont; Tredaptive; Tredaptive Extended-release tab; Trevaclyn

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; Merck Sharp & Dohme
  • Class Antihyperlipidaemics; Indoles; Nicotinic-acids; Small molecules
  • Mechanism of Action GPR109A receptor agonists; GPR109B receptor agonists; Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Dyslipidaemias; Hypercholesterolaemia
  • Discontinued Atherosclerosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 09 Mar 2013 Withdrawn for Dyslipidaemias in Hong Kong (PO)
  • 09 Mar 2013 Withdrawn for Dyslipidaemias in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top